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The BDNF Val66Met polymorphism moderates the
relationship between cognitive reserve and executive function
DD Ward1,2, MJ Summers2,3, NL Saunders2, K Ritchie4,5, JJ Summers1,6 and JC Vickers1,2
The concept of cognitive reserve (CR) has been proposed to account for observed discrepancies between pathology and its clinical
manifestation due to underlying differences in brain structure and function. In 433 healthy older adults participating in the
Tasmanian Healthy Brain Project, we investigated whether common polymorphic variations in apolipoprotein E
(APOE) or brain-derived neurotrophic factor (BDNF) inﬂuenced the association between CR contributors and cognitive function in
older adults. We show that BDNF Val66Met moderates the association between CR and executive function. CR accounted for 8.5% of
the variance in executive function in BDNF Val homozygotes, but CR was a nonsigniﬁcant predictor in BDNF Met carriers. APOE
polymorphisms were not linked to the inﬂuence of CR on cognitive function. This result implicates BDNF in having an important role
in capacity for building or accessing CR.
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INTRODUCTION
Observations of signiﬁcant heterogeneity in the clinical manifesta-
tion of underlying brain pathology has led to the development of
the concept of cognitive reserve (CR).1 CR level is considered to be
determined by both biological and environmental exposures,
notably intelligence,2 education3 and occupational attainment.4
Epidemiological evidence further supports the notion of CR by
demonstrating consistent associations between lifestyle charac-
terized by intellectual and social engagement and slower
cognitive decline.5 In older persons, functional magnetic reso-
nance imaging studies of neural networks suggest that differences
in functionally connected regions in persons with high CR may
enhance the compensatory capacity of individuals in the face of
both normal and pathological brain aging.6 Alzheimer’s disease
(AD) patients with higher educational and occupational attain-
ment have more rapid cognitive decline than those with lower
attainment, consistent with the idea that at a given common level
of severity, underlying AD pathology is more advanced in patients
with more CR.7 That individuals with higher CR display greater
resistance to the effects of neuropathology is likely due to induced
cortical plasticity caused by a prolonged mismatch between
functional supply and task demands,8 resulting in more ﬂexible
and denser neural networks.9 As adult cognitive function
and cognitive aging show signiﬁcant heritability,10 research
examining the interaction between genes and CR proxies is
justiﬁed. The most likely candidate genes for CR are those that
interact with environmental factors to induce effects on cognitive
functions.11
One gene that potentially interacts with CR is apolipoprotein E
(APOE). Although it has been established that speciﬁc allelic
variants in the APOE gene are associated with risk for late-onset
AD,12 it is less clear whether other allelic variants of the APOE gene
impart healthy cognitive function.13,14 However, APOE polymorph-
isms have been shown to exert divergent neuroprotective
effects.15,16 For example, the presence of APOE ε4 is associated
with an increased rate of AD-related hippocampal atrophy17 and
impaired synaptic plasticity18 when compared with APOE ε4
noncarriers. Lifestyle activities that require cognitive effort (for
example, completing puzzles and playing chess) predict verbal
ﬂuency and semantic memory recall in APOE ε4 noncarriers but
not in carriers.19
A second gene that may be associated with CR is brain-derived
neurotrophic factor (BDNF). The encoded neurotrophin is crucial to
neuronal survival, maintenance, neurogenesis and synaptic
plasticity.20,21 The BDNF Val66Met polymorphism affects activity-
dependent secretion of BDNF, with the Met allele associated with
reduced depolarization-induced BDNF release into the synapse.22
BDNF Met alleles have been associated with reduced memory
capacity,22 but not consistently.14,23 Similar to APOE, impaired
synaptic plasticity is a feature of BDNF Met alleles.24,25
Synaptic plasticity is a key mechanism that facilitates the
development of CR.26 Research to date has examined CR in the
presence of pathology; however, as CR is developmentally
acquired through both intrinsic (biologic) factors such as genetic
heritability as well as extrinsic (environmental) factors such as
education, it is imperative to examine the development of CR prior
to the onset of clinical symptomatology. We aimed to use baseline
data from the Tasmanian Healthy Brain Project (THBP)27 to
investigate the relationship between CR, cognitive function and
APOE and BDNF Val66Met polymorphisms in healthy older adults
(50–79 years). We tested two hypotheses. First, that higher CR is
associated with better cognitive performance. Second, that BDNF
Val66Met and APOE polymorphisms independently moderate the
association between CR and cognitive performance, with carriers
of the putative detrimental alleles (Met and ε4, respectively)
showing a reduced inﬂuence of CR when compared with
noncarriers.
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The participants were 433 community-residing healthy older adults, aged
50–79 years, who were all native-English speakers or spoke English as a
primary language. They had consented to participate in the THBP, which
involves comprehensive annual assessments of neuropsychological, health
and psychosocial function. The THBP is a prospective longitudinal study
examining whether late-life education provides protection from dementia
through enhancement of CR.27 Subjects were excluded from participating
if they had a history of any condition independently associated with
impairments to cognitive function (dementia; multiple sclerosis; previous
signiﬁcant head injury requiring hospitalization; epilepsy; history of
cerebrovascular complications; diabetes—poorly controlled; blood pres-
sure complications—poorly controlled; other neurological disorders;
chronic obstructive pulmonary disease; heart disease; blindness; deafness;
psychiatric disorder). The THBP was conducted with full approval from the
Tasmania Human Research Ethics Network and in accordance with the
ethical guidelines of the National Health and Medical Research Council of
Australia.
Materials
A comprehensive test battery was completed by subjects as described in
detail elsewhere.27 Multiple objective measures were used to screen
participants for: symptoms of dementia, clinically signiﬁcant symptoms of
depression or anxiety, general health, medical conditions, prescription
medication use, drug and alcohol use, handedness, height, weight, marital
status, educational and occupational history.
Neuropsychological assessment battery
Cognitive functions were assessed using tests that measured learning and
memory, working memory, executive function and language processing,
and are described in detail elsewhere.27 The test battery incorporated
standardized neuropsychological measures with established reliability and
validity in the measurement of: visual and verbal episodic memory, visual
and verbal immediate memory span, visual and verbal working-memory
capacity, word knowledge, semantic memory recall, language comprehen-
sion and multiple executive functions including attention, concentration,
information-processing speed, decision-making capacity and reaction time.
Assessment of CR
To generate an estimate of CR, we used a previously developed equation
to combine measures of lifetime education, occupational attainment,
intelligence and participation in cognitively stimulating leisure activities
into a single variable.28 The Wechsler Test of Adult Reading29 was used to
estimate premorbid intellectual capacity, the Lifetime of Experiences
Questionnaire30 to quantify prior lifetime participation in cognitive
activities and the Medical Health Screening questionnaire to record the
number of years of prior formal education.27 Brieﬂy, factor analysis
(principal components extraction method) with Varimax rotation com-
bined seven CR proxy variables into four signiﬁcant latent factors. In
combination, these factors explained 77.10% of the variance in the data
set. Z-scores for each component were generated using the regression
method, with an estimate of overall CR resulting from the addition of each
factor score into the total score.
Genotyping
DNA samples were collected with Oragene DNA self-collection kits
(Genotek, ON, Canada, 2012). APOE and BDNF genotypes were determined
through one-step ampliﬁed refractory mutation system PCR31 and
subsequent gel electrophoresis. For APOE, rs429358 and rs7412 were
determined by following the method described by Donohoe et al.32 For
BDNF, Val66Met was determined by following the method described by
Sheikha et al.33 PCR ampliﬁcations were undertaken in a 12-μl reaction
volume that contained ~ 50 ng of genomic DNA. PCR amplicons were
resolved on 2% agarose gel. Genotyping was repeated on samples to
ensure accuracy.
Procedure
Trained assessors carried out the neuropsychological testing as part of the
baseline THBP assessments.27 The assessment process took ~ 4 h to
complete and was undertaken in a quiet room. Subjects were encouraged
to take 10-min breaks when required to reduce fatigue.
Data analysis
Prior to the main analyses, variables of CR and cognitive function were
generated. To represent CR, we used a previously developed equation to
create a comprehensive single-point measure of the construct.28
Standardized scores of CR variables (Table 1) were entered into the CR
equation to yield total CR for each subject. Composite cognitive domain
Table 1. Descriptive statistics for the study population stratiﬁed by APOE and BDNF genotypes
Characteristic N APOE status BDNF status
ε4- ε4+ P Met- Met+ P
Demographics
Age (years) 422 62.31 (6.83) 61.67 (6.69) 0.53 62.16 (6.85) 61.99 (6.68) 0.81
Gender (male/female %) 422 31.9/68.1 35.8/64.2 31.6/68.4 36.4/63.6
Genotype (%) 422 67.5 32.5 66.8 33.2
Screening
DRS-2 AEMSS 422 11.93 (2.12) 12.16 (2.03) 0.56 12.04 (2.10) 11.93 (2.08) 0.61
HADS anxiety 421 5.21 (3.12) 5.35 (2.97) 0.39 5.35 (3.19) 5.07 (2.80) 0.38
HADS depression 421 2.36 (2.14) 2.58 (2.34) 0.24 2.42 (2.26) 2.45 (2.10) 0.91
Cognitive reserve28
WTAR Est. FSIQ 421 112.57 (5.39) 112.16 (5.94) 0.86 112.40 (5.49) 112.51 (5.76) 0.85
Prior education (years) 422 14.13 (2.81) 13.61 (2.59) 0.19 13.73 (2.72) 14.44 (2.75) 0.01
LEQ young adulthood speciﬁc 421 16.19 (7.93) 15.51 (7.65) 0.41 15.56 (7.61) 16.78 (8.25) 0.13
LEQ young adulthood nonspeciﬁc 421 24.71 (5.54) 24.93 (5.11) 0.19 24.42 (5.45) 25.52 (5.23) 0.05
LEQ midlife speciﬁc 420 19.07 (5.01) 19.06 (4.93) 0.45 19.09 (4.82) 19.02 (5.28) 0.90
LEQ midlife nonspeciﬁc 420 24.37 (5.55) 24.36 (5.60) 0.46 24.08 (5.72) 24.93 (5.20) 0.14
LEQ continuing education bonus 418 10.22 (8.79) 9.38 (8.01) 0.46 9.95 (8.45) 9.94 (8.75) 0.99
Abbreviations: AEMSS, age- and education-corrected Mayo Older American normative Studies (MOANS) scaled score; APOE, apolipoprotein E; BDNF, brain-
derived neurotrophic factor; DRS-2, Dementia Rating Scale-2; FSIQ, full-scale intelligence quotient; HADS, Hospital Anxiety and Depression Scale; LEQ, Lifetime
of Experiences Questionnaire; WTAR, Wechsler Test of Adult Reading. Note: data represented are mean values (s.d.) for continuous variables and proportions
for categorical variable. ε4− /Met− =participants not carrying the APOE ε4/BDNF Met alleles; ε4+/Met+=participants carrying at least one copy of the APOE
ε4/BDNF Met alleles.
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variables were also computed through a principal components analysis that
combined measured variables (raw scores) into speciﬁc domains (episodic
memory, working memory, executive function and language processing).
The extracted factor that explained the highest proportion of variance was
retained to represent each cognitive domain (Table 2). The APOE and BDNF
predictor variables were coded as carriers or noncarriers of the detrimental
allele, ε4 and Met, respectively. To assist in interpretation, subjects with the
APOE ε2/ε4 polymorphism were excluded from the analysis.
The primary analyses used PROCESS v2.11 (ref. 34) to test whether CR
was associated with cognitive function, either independently or through
CR×APOE/CR × BDNF interaction. PROCESS is a computational tool for
path analysis-based moderation and mediation analysis that provides
coefﬁcient estimates for total, direct and indirect effects of variables using
ordinary least squares regression. Prior to analysis, the continuous
independent predictor (CR) was mean-centered to reduce potential
multicollinearity. Subsequent analyses involved testing for direct effects
of predictors (CR, APOE and BDNF) and indirect effects of possible CR
moderators (APOE and BDNF) on cognitive function domains while
covarying for age and gender. First, regression equations were ﬁtted to
cognitive domain data and the predictive capacity of age, CR and gender
were assessed. Second, APOE/BDNF data and corresponding CR-gene
product variables were entered to test for CR moderation in separate
models. An alpha value of 0.05 was used for all statistical tests, and all data
were analysed in SPSS v21 (IBM, Armonk, NY, USA).
Table 2. Factor analysis results for composite cognitive domain variables
Cognitive domain Initial eigenvalue Variable N Mean s.d. Loading
Episodic memory 2.50 (62.46%) RAVLT 1-5 total 407 52.96 8.92 0.76
LM I immediate recall total 407 48.43 8.07 0.89
LM II delayed recall total 407 30.29 6.28 0.86
PAL ﬁrst trial memory score 407 18.35 3.46 0.63
Working memory 2.04 (50.93%) Digit span 407 18.63 3.90 0.76
Letter–number sequencing 407 11.59 2.40 0.79
SWM between errors 407 25.36 18.64 − 0.63
SSP length 407 5.75 1.20 0.66
Executive function 1.80 (59.83%) Stroop trial C 403 26.26 7.63 0.76
RVP Aʹ 403 0.91 0.05 − 0.81
TMT trial B 403 59.09 18.82 0.75
Language processing 1.88 (62.81%) WAIS vocabulary 421 56.62 6.23 0.88
WAIS comprehension 421 26.21 3.33 0.77
Boston naming test 421 57.49 3.42 0.72
Abbreviations: LM, logical memory; RAVLT, Rey auditory verbal learning test; RVP, rapid visual processing; SSP, spatial span; SWM, spatial working memory; TMT,
trail making test; WAIS, Wechsler Adult Intelligence Scale. Note: data in parentheses represent the proportion of variance (%) explained by the resulting factor.
Table 3. Results of the regression analyses for cognitive domain data
Cognitive domain Predictor N β s.e. t P R2 change F
Episodic memory Age 401 − 0.04 0.01 − 6.25 o0.01
CR 401 0.05 0.02 2.56 0.01
Gender 401 0.53 0.10 5.40 o0.001
APOE 401 − 0.06 0.10 − 0.57 0.57
BDNF 401 − 0.01 0.10 − 0.09 0.93
CR×APOE 401 − 0.01 0.04 − 0.32 0.75 0.00 0.10
CR×BDNF 401 − 0.06 0.04 − 1.40 0.16 0.00 1.97
Working memory Age 401 − 0.05 0.01 − 7.18 o0.01
CR 401 0.07 0.02 3.26 o0.01
Gender 401 − 0.10 0.10 − 1.03 0.31
APOE 401 0.06 0.10 0.64 0.52
BDNF 401 − 0.12 0.10 − 1.19 0.24
CR×APOE 401 0.04 0.04 0.99 0.33 0.00 0.97
CR×BDNF 401 0.04 0.04 0.98 0.33 0.00 0.96
Executive function Age 397 − 0.06 0.01 − 9.25 o0.01
CR 397 0.11 0.02 5.40 o0.01
Gender 397 0.19 0.10 2.01 0.045
APOE 397 0.13 0.10 1.36 0.21
BDNF 397 − 0.00 0.09 − 0.05 0.96
CR×APOE 397 0.02 0.04 0.41 0.68 0.00 0.17
CR×BDNF 397 − 0.08 0.04 − 1.97 0.049 0.01 3.88
Language processing Age 415 0.00 0.01 0.36 0.62
CR 415 0.16 0.02 8.00 o0.01
Gender 415 − 0.16 0.10 − 1.67 0.10
APOE 415 0.08 0.10 0.79 0.43
BDNF 415 − 0.07 0.10 − 0.78 0.44
CR×APOE 415 0.03 0.04 0.60 0.55 0.00 0.36
CR×BDNF 415 − 0.07 0.04 −1.35 0.18 0.00 1.82
Abbreviations: APOE, apolipoprotein E; BDNF, brain-derived neurotrophic factor; CR, cognitive reserve. Note: APOE and BDNF main and interaction effects
were tested in separate models. Bold values are statistically signiﬁcant values with Po0.05.
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RESULTS
Participants
The sample comprised 433 participants with a mean age of 62.16
years (s.d. = 6.81) and an above-average estimated full-scale
intelligence quotient (M= 112.47, s.d. = 5.52). Participants were
mostly female (66.7%) and had completed an average of 13.97 (s.
d. = 2.73) years of formal education. To assist in interpretation, 11
participants were excluded due to possessing the APOE ε2/ε4
genotype. The characteristics of the remaining participants are
presented in Table 1. The APOE (χ2(1,N= 422) = 0.02, P= 0.90) and
BDNF Val66Met (χ2(1,N= 422) = 0.31, P= 0.58) genotype distributions
did not differ signiﬁcantly from the Hardy–Weinberg equilibrium.
CR, age and gender
PROCESS was used to ﬁt linear regression models to the cognitive
domain data. With the age, CR and gender predictors entered,
signiﬁcant models were produced for all assessed cognitive
functions: episodic memory (F(3,397) = 25.53, Po0.01, R2 = 0.16);
working memory (F(3,397) = 19.66, Po0.01, R2 = 0.13); executive
function (F(3,397) = 37.54, Po01, R2 = 0.22); and language proces-
sing (F(3,411) = 23.79, Po0.01, R2 = 0.15). The CR variable had a
signiﬁcant positive association with each cognitive domain
(Po0.01), whereas the age variable had a signiﬁcant negative
association with each cognitive domain (Po0.01), excluding
language processing (P= 0.62). The gender variable had a
signiﬁcant positive association with episodic memory (Po0.01)
and executive function (Po0.05), whereby females outperformed
males. The individual contribution that each predictor made to the
model is detailed in Table 3.
Gene–CR interactions
We then assessed whether the inclusion of APOE/BDNF
Val66Met allelic carrier data signiﬁcantly improved the ﬁt of the
models. Notably, no signiﬁcant main effects of genetic predictors,
APOE or BDNF Val66Met, were identiﬁed for any cognitive domain.
A moderation analysis (PROCESS) was then conducted examining
whether the inclusion of CR ×APOE or CR × BDNF interaction terms
signiﬁcantly improved the ﬁt of regression models. Results
indicated that a single genetically based moderation effect on
CR was present (Table 3). Speciﬁcally, inclusion of the CR× BDNF
Val66Met interaction term led to a signiﬁcant increase in the
amount of variance in executive function explained by the model
(ΔR2 = 0.01, P= 0.05). Simple slopes analysis was conducted in
order to determine the basis of the moderation effect of BDNF
polymorphism on the conditional effect between CR and
executive function, and to determine whether the slopes
statistically differed from zero for BDNF Met carriers and
noncarriers, separately. These analyses indicate that a signiﬁcant
positive relationship between CR and executive function was
identiﬁed in BDNF Val homozygotes (β= 0.13, t= 5.56, s.e. = 0.02,
Po0.01), but was not evident in BDNF Met carriers (β= 0.05,
t= 1.52, s.e. = 0.03, P= 0.13). In BDNF Val homozygotes, CR
accounted for a signiﬁcant 8.6% of variance in executive function
performance. In BDNF Met carriers, CR accounted for a non-
signiﬁcant 1.5% of variance in executive function performance.
Simple slopes are presented in Figure 1.
DISCUSSION
The present study was designed to investigate whether a
composite measure of CR was associated with healthy cognitive
function, either independently or through an interaction with
genetic APOE/BDNF Val66Met polymorphic data, in participants of
the THBP. The ﬁrst hypothesis, that higher CR is associated with
better cognitive performance, was supported. Our sample showed
signiﬁcant positive relationships between CR and cognitive
function across all cognitive domains, after accounting for the
effects of age and gender. The second hypothesis, that BDNF Met
carriers and APOE ε4 carriers would display a weaker relationship
between CR and cognitive function when compared with their
respective noncarriers, was partially supported. The analyses
revealed a single signiﬁcant CR × BDNF interaction in predicting
age- and gender-adjusted executive function performance. In this
regard, the relationship between CR and executive function was
moderated by BDNF genotype, with a positive association
between the variables present in BDNF Val homozygotes that
was absent in BDNF Met carriers.
CR is of interest due to its potential role in varying the age at
which an individual develops dementia and the subsequent rate
of dementia progression experienced,9 as well as mitigating
against the effect of other central nervous system insults.
However, although previous research frequently highlights the
relationship between increased CR and reduced dementia
incidence,35 other investigations have suggested that CR is also
involved in nonpathological cognitive function. For instance,
during a memory task, higher functional connectivity, indicative of
heightened cognitive effort, is found in subjects with lower CR,
despite achieving the same level of performance as those with
higher CR.36 Similarly, CR was positively associated with brain
volume but negatively associated with cortical activity during a
visual encoding task.37 Such ﬁndings are consistent with the CR
hypothesis, which posits that CR is implicated in nonpathological
cognitive function,1 particularly in relation to cerebral network
efﬁciency.38 Our ﬁnding, that CR was positively associated with all
four assessed cognitive domains, adds further evidence that CR
accounts for healthy cognitive function and that cognitive
associations with CR are not limited to protection from the clinical
expression of pathological processes. At the very least, it may be
that higher scores on CR proxy variables would result in a delayed
onset of dementia due to the pre-existing cognitive advantage
afforded to high-CR individuals through greater education,
occupational attainment, intelligence and participation in cogni-
tively stimulating lifestyle activities. In high-CR individuals a
greater loss of cognitive function, resulting from greater levels
of neuropathology, would be required to produce functional
Figure 1. BDNF Val66Met moderates the relationship between CR
and executive function scores. The plot represents age- and gender-
adjusted executive function performance as predicted by the
composite CR proxy variable for those with low CR (CR scores less
than the mean–1s.d.) and high CR (CR scores greater than the mean
+1s.d.) for BDNF Met carriers and Val homozygotes, separately. BDNF,
brain-derived neurotrophic factor; CR, cognitive reserve.
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deﬁcits of sufﬁcient severity to meet diagnostic criteria for
dementia.
A comprehensive review of the evidence for genetic contribu-
tions to CR noted that those genes that interact with environ-
mental factors to produce a cognitive effect are the most likely
candidates.11 In our study, we identiﬁed a signiﬁcant moderating
inﬂuence of BDNF Val66Met polymorphism on the relationship
between CR and executive function. In those individuals who were
BDNF Val homozygotes, a one-point increase in CR was associated
with a 0.13-point increase in executive function. Comparatively, in
those individuals who were BDNF Met carriers, a one-point
increase in CR was associated with a nonsigniﬁcant 0.05-point
increase in executive function. This ﬁnding is of particular
importance due to the overlap between CR and executive
function.39 Cognitive ﬂexibility is suggested to be both one of
the processes that mediate the compensatory beneﬁts associated
with higher CR1 and a mental ability considered as a component
of executive function.40 In addition, both CR and executive
function are associated with frontal lobe activity,41,42 with a
positive association of education and frontal engagement present
in older adults that is not seen in younger adults.42 Clinical studies
conﬁrm that there is an age-related decline in executive
function,43 and that the onset of dementia is often characterized
by early impairment of executive function.44 Overall, our ﬁndings
indicate that although BDNF Val homozygotes show normal
positive associations between CR and executive function, BDNF
Met carriers have a reduced inﬂuence of CR on executive function.
One explanation for the signiﬁcant moderation of CR by BDNF
Val66Met lies within differences in biochemical responses to
cognitively stimulating environments. Namely, individuals with
BDNF Met alleles may receive a lesser impact on neurological
function of exposure to environmental activities that contribute to
CR. Previous research has demonstrated that long-term exposure
to cognitively stimulating environments is associated with a
widespread increase in BDNF expression in the brain,45 but BDNF
Met carriers have both reduced activity-dependent secretion of
BDNF22 and impaired synaptic capacity for long-term potentia-
tion/depression.46 Consequently, for two individuals exposed to
the same level of extrinsic environmental stimulation, the
individual who carries the BDNF Met polymorphism exhibits
reduced synaptic plasticity and neuronal restructuring subsequent
to environmental stimulation and consequently displays lowered
functional capacity due to the negative intrinsic effect of BDNF
Met polymorphism on development of CR. Studies examining the
inﬂuence of environmental enrichment in rodents report that
environmental enrichment only confers beneﬁts in the presence
of BDNF protein. For example, environment-induced hippocampal
neurogenesis occurs only in the presence of BDNF47 and
upregulation of BDNF by stimulating environments promotes
neural plasticity.48
The results of the present study have several implications. First,
as higher CR was associated with higher overall cognitive function,
CR exerts an impact on healthy cognitive function, independent of
dementia. Although the cross-sectional analyses employed in the
present study do not allow comment on the relationship between
CR and rate of age-related cognitive decline, the results indicate
that, at the very least, CR may beneﬁt cognitive function at older
age due to the persistent effects of improved cognitive function.
Second, the results of the present study demonstrate that a
genetic factor moderates the effect that CR has on cognitive
function. Speciﬁcally, BDNF Met carriers showed a reduced
relationship between CR and executive function when compared
with noncarriers. Although this effect was found within a relatively
small sample size, this result provides initial evidence that BDNF
Met carriers may have a partial ‘disconnect’ between CR and
cognitive function, and future longitudinal analyses will examine
whether BDNF Val66Met mediates environmentally generated
protection from dementia. In relation to noncarriers, the
identiﬁcation of persons with very high resistance to the
functional consequences of brain pathology may provide a cohort
for the development of future epigenetic strategies to reduce
dementia in the face of AD disease progression.
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